ArticleNeuro-oncology advances
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.British journal of haematology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma restricted to the CNS in which outcomes cannot be reliably predicted. The International PCNSL Collaborative Group developed standardized response assessment utilizing 2-dimensional (2D) Magnetic Resonance Imaging (MRI) tumor measurements. Considerable challenges of this approach exist due to many reasons. Recent glioblastoma and PCNSL data demonstrated that radiological assessment of baseline 3-dimensional volume (3DV) as well as 3DV reduction (3DVR) may be a sensitive prognostic parameter. Methods: Our multicentre retrospective study evaluated semiautomated 3DV in 74 PNCSL patients undergoing curative-intent chemoimmunotherapy. Results: Baseline tumor 3DV was not associated with survival. Compared to 3DVR < 58% (ROC-determined threshold based on our cohort), both interim and End-of-Treatment (EOT) 3DVR ≥ 58% in responding patients were associated with statistically significant prolonged 2-year progression-free survival (PFS) (interim: 73% (95%CI 57-83) versus 22% (95%CI 3-51), Conclusion: Although PCNSL tumor 3DV at baseline is not associated with survival outcomes, 3DVR of ≥58% in interim and EOT confers superior PFS and OS. Whereas, no difference in survival was observed using standard 2D CR versus PR response assessment at the same time-points. 3DV calculations may offer a sensitive method of response assessment for PCNSL. We are currently validating this in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.